Abstract

Autophagy is an evolutionally conserved catabolic process that degrades cells to maintain homeostasis. Cisplatin-activated autophagy promotes the expression of circ-PKD2, which plays a role as a tumor suppressor gene in the proliferation, migration, and invasion in oral squamous cell carcinoma (OSCC). However, the role of circ-PKD2 in regulating the sensitivity of OSCC patients to cisplatin remains to be elucidated. Overexpression of circ-PKD2 increased the formation of autophagosomes in OSCC cells and activation of proteins, such as LC3 II/I. Its activation effect on autophagy was, however, alleviated by 3-MA. Bioinformatics analyses and double luciferases reporter assays conducted in this study confirmed the existence of targeted relationships between circ-PKD2 and miR-646 and miR-646 and Atg13. Functional experiments further revealed that miR-646 reversed the autophagy and apoptosis effects of circ-PKD2 in OSCC cells treated with cisplatin. In addition, circ-PKD2 promoted the expression of ATG13 by adsorption of miR-646. Its interference with Atg13 alleviated the activation effects of circ-PKD2 on autophagy and apoptosis of miR-646. Notably, the in vivo animal experiments also confirmed that circ-PKD2 inhibited tumor proliferation and activated autophagy in OSCC cells. This study provides a theoretical basis for using circ-PKD2 as a target to regulate the sensitivity of OSCC patients to cisplatin, thus increasing its chemotherapeutic effects.

Highlights

  • Oral squamous cell carcinoma (OSCC) is a common head and neck malignant tumor

  • This study revealed that circ-PKD2 promoted the sensitivity of OSCC to cisplatin both in vitro and in vivo

  • Functional experiments further demonstrated that the expression of circ-PKD2 and autophagy-related proteins increased in OSCC cells treated with cisplatin

Read more

Summary

INTRODUCTION

Oral squamous cell carcinoma (OSCC) is a common head and neck malignant tumor. It has a high prevalence and incidence, with 300,000 new cases and 145,000 deaths attributed to OSCC reported globally every year [1]. This study revealed that circ-PKD2 promoted the sensitivity of OSCC to cisplatin both in vitro and in vivo. Functional experiments further demonstrated that the expression of circ-PKD2 and autophagy-related proteins increased in OSCC cells treated with cisplatin. We hypothesize that circ-PKD2 potentially regulates the sensitivity of OSCC cells to cisplatin by upregulating autophagy. Bioinformatics analyses revealed that circ-PKD2 targets miR-646, which inhibited ATG13, increasing the expression of ATG13. Official journal of CDDpress targeted miR-646, up-regulated autophagy which promoted Dual Luciferase Assay Kit (Promega) according to the manufacturer’s the sensitivity of OSCC cells to cisplatin, This study provides a protocol. Theoretical basis for circ-PKD2 as a target to regulate the sensitivity of OSCC patients to cisplatin, increasing its chemotherapeutic effects.

MATERIALS AND METHODS
Findings
RESULTS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call